Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Study results on HDR-BT as a monotherapy using more than 3 fractions

From: Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer

Study (reference) n M. follow-up (vrs) Risk HDR schedule ADT Toxicity score G2 GI late toxicity G3 GI late toxicity G2 GU late toxicity G3 GU late toxicity bRFS*
Demanes (1) 298 5.2 L 81%, I 18%, H 1% 6 × 7 Gy (53%) 24% CTCAE 3.0 <1% <1% 10% 3% 97%
4 × 9.5 Gy (47%)
Zamboglou (2) 718 4.4 L 55%, I 25%, H 20% 4 × 9.5 Gy (68%) 21.4% CTCAE 3.0 ~1% 1.6% ~20% 3.5% 94%
3 × 11.5 Gy (32%)
Yoshioka (3) 112 5.4 L 13%, I 26%, H 61% 9 × 6 Gy 84% CTCAE 3.0 12%# 3%# 12%# 3%# 83%
Hoskin (4) 197 0.5-5 L 4%, I 52%, H 44% 4 × 8.5 Gy (15%) 80% RTOG 1% 4-13% 20-30% 3-14% 95%
4 × 9 Gy (13%)
3 × 10.5 Gy (55%)
2 × 13 Gy (17%)
Rogers (5) 284 2.7 I 100% 6 × 6.5 Gy 16% RTOG 0% 0% 1.8% 0.7% 83%
Present study 36 6.9 L 78%, I 22% 4 × 9,5 Gy 14% CTCAE 3.0 0% 0% 28% 19% 97%
  1. Abbreviations: M median, G grade, GU genitourinary, GI gastrointestinal, L low, I intermediate, H high, bRFS biochemical recurrence-free survival, *according to the Phoenix criteria, #genitourinary and gastrointestinal toxicity not discriminated.